Cipher Pharmaceuticals (TSE:CPH) Receives “Hold” Rating from Bloom Burton

Bloom Burton restated their hold rating on shares of Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) in a research note published on Monday, Zacks.com reports.

Cipher Pharmaceuticals stock opened at C$1.21 on Monday. The stock’s 50 day moving average is C$1.23 and its 200 day moving average is C$1.43. The company has a debt-to-equity ratio of 62.34, a current ratio of 1.06 and a quick ratio of 0.98. The firm has a market cap of $33.10 million and a P/E ratio of 18.06. Cipher Pharmaceuticals has a one year low of C$1.11 and a one year high of C$3.66.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients.

Recommended Story: Are sell-side analysts objective?

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit